-
JCO: Lower dose, better efficacy-Tamoxifen benefits more women!
Time of Update: 2021-03-26
5 mg of tamoxifen, the reduction in breast density was equivalent to that of the standard dose of 20 mg, but with fewer side effects.
5 mg of tamoxifen, the reduction in breast density was equivalent to that of the standard dose of 20 mg, but with fewer side effects.
-
A new treatment plan for advanced renal cell carcinoma-lenvatinib combined with pembrolizumab
Time of Update: 2021-03-26
In a multinational phase 3 trial, patients with previously untreated advanced renal cell carcinoma were randomly divided into 3 groups and received lenvatinib + pembrolizumab (Len/Pem; lenvatinib daily, Pembrolizumab is administered intravenously every 3 weeks), lenvatinib + everolimus (Len/Eve; both drugs are administered daily) or sunitinib (treatment for 4 weeks, drug withdrawal for 2 weeks) treatment.
-
Hypoxia thinking after three months of squatting
Time of Update: 2021-03-26
It is very necessary to study the molecular markers related to hypoxia in breast cancer.
Hypoxia-related DEG prognostic markers and risk characteristics construction Figure 4.
Identification of hypoxia-related differential expression candidate miRNAs and enrichment analysis Figure 5.
Identification of hypoxia Oxygen-related differential expression candidate miRNA 6.
-
Significantly prolong survival, first-line treatment of esophageal cancer has made an important breakthrough in the past 30 years
Time of Update: 2021-03-26
The press release pointed out that this is the first anti-PD-1 immune combination therapy approved by the FDA for the first-line treatment of this patient group, and represents a major breakthrough in the first-line treatment of esophageal cancer in the past 30 years.
-
PD-1 antibody "new partner": fusion IL-21
Time of Update: 2021-03-25
In a study published on Nature Communications on February 11, researchers from the Institute of Biophysics, Chinese Academy of Sciences developed a PD-1 antibody and IL-21 fusion protein (PD-1AB21), which can Targeting IL-21 to T cells expressing PD-1 while blocking the interaction between PD-1 and PD-L1.
-
In-depth interpretation of PDB: In 2020, the market in all fields will fall by 13%! Osimertinib...
Time of Update: 2021-03-25
Figure 1 Analysis of sales growth in the overall sample market over the years in 2020
Figure 2 Analysis of sales growth of various treatment categories in the overall sample market over the years
-
"Pharmaceutical Speed Reading Society" China's new crown therapeutic antibody new drug was approved in Europe and the United States for emergency use...
Time of Update: 2021-03-25
On March 15th, Jingfeng Pharmaceutical issued an announcement stating that its holding subsidiary had recently received a notice from the FDA that the abbreviated new drug application for Lincomycin Hydrochloride Injection has been approved.
-
CStone's RET inhibitor "Platinib Capsules" will be approved soon
Time of Update: 2021-03-25
The drug's marketing application is mainly based on the positive data of the ARROW study, which is an evaluation of the safety, tolerability and efficacy of pralsetinib in patients with RET fusion-positive NSCLC, thyroid cancer, and other advanced solid tumors with RET mutations.
-
In 2020, the licensing cooperation between Chinese and foreign pharmaceutical companies is surging
Time of Update: 2021-03-25
Focusing on clinical trials, commercialization and data sharing, multinational pharmaceutical groups have reached a total of 271 cross-border licensing cooperation agreements with Chinese pharmaceutical companies in 2020.
-
Recruitment of medical talents (updated on 03.12)
Time of Update: 2021-03-25
[Job requirements] Recognize the Green Valley culture, be positive, have passion, have methods, dare to challenge yourself, and innovate work; college degree or above, medicine, pharmacy, nursing and other related majors are preferred, and those with experience are preferred, with neurology, Experience in psychiatry and geriatric promotion is preferred!
-
A batch of large varieties meets the conditions of the fifth batch of centralized procurement
Time of Update: 2021-03-25
With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
-
Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted
Time of Update: 2021-03-25
Last week, the FDA issued a total of 4 orphan drug qualifications, including 3 small molecule targeted drugs and 1 fusion protein, including the IL-2 selective agonist nemvaleukin alfa (ALKS 4230) developed by Alkermes to treat mucosal melanoma.
And RNR BioMedical's dipeptide small molecule drug ubenimex for the treatment of chronic myelogenous leukemia.
-
BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor...
Time of Update: 2021-03-25
Recently, BeiGene announced that a phase 1 clinical trial of its in-development hematopoietic stem cell kinase 1 (HPK1) inhibitor BGB-15025 has completed its first patient administration.
In preclinical studies, inhibiting HPK1 can effectively promote T cell activation, thereby enhancing the anti-tumor activity of PD-1 inhibitors including BeiGene's Bezean (Tilelizumab).
-
China's first epothilone breast cancer class 1 new drug Utidelone approved for marketing
Time of Update: 2021-03-25
Research data shows that for patients with advanced breast cancer who have used anthracyclines and taxanes in the past, the overall survival of Utidrolone combined with capecitabine is significantly prolonged from 15.
-
Professor Wang Liwei: Progress in medical treatment of liver cancer
Time of Update: 2021-03-22
02 During the 2020 ASCO conference, a phase III study of apatinib versus placebo in the second-line treatment of Chinese patients with advanced liver cancer was announced.
-
Review and inventory | recent CAR-T therapy related research progress and new drug approval collection
Time of Update: 2021-03-22
For details, please click: CAR-T cell therapy Idecabtagene Vicleucel in the treatment of relapsed and refractory multiple myeloma: Results of the Phase II KarMMa study, Professor Ghulam Rehman Mohyuddin and others searched from January 1, 2013 to November 15, 2020 in manuscript or abstract All prospective trials involving ≥2 patients with MM have been published in the form to evaluate the efficacy and safety of CAR-T in the treatment of MM.
-
FDA News | VEGFR TKI Breaks Through Refractory Renal Cell Carcinoma!
Time of Update: 2021-03-22
On March 10, 2021, tivozanib was approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC).
-
The essence of the March 5, 2021 issue of Science
Time of Update: 2021-03-22
html" target="_blank">Science: New research has identified a variety of cardiac progenitor cell populations in the mouse embryonic heart region doi:10.
html" target="_blank">Science: New research has identified multiple cardiac progenitor cell populations in mouse embryonic heart regions doi:10.
-
Breast cancer death risk increased by 85%!
Time of Update: 2021-03-22
Recently, a study conducted by researchers at the State University of New York at Buffalo (University at Buffalo) found that regular consumption of sugar-sweetened beverages can also increase the risk of death for breast cancer patients, including all causes (caused by various causes) The risk of death and the risk of specific (caused by breast cancer) death.
-
Apatamide + ADT in the treatment of high-risk/high-tumor-burden mHSPC patients has a rapid, deep, and lasting decrease in PSA, and significant benefits for 4 years!
Time of Update: 2021-03-22
*For medical professionals to read only for reference, high-risk/high-tumor-burden mHSPC patients receive apatamide treatment, the PSA level decreases rapidly, deeply, and lastingly, with significant curative effect and good safety.
